World Journal of Nutrition and Health
ISSN (Print): 2379-7819 ISSN (Online): 2379-7827 Website: http://www.sciepub.com/journal/jnh Editor-in-chief: Srinivas NAMMI
Open Access
Journal Browser
Go
World Journal of Nutrition and Health. 2014, 2(3), 33-34
DOI: 10.12691/jnh-2-3-1
Open AccessReview Article

Silymarin: Insights into Properties and Therapeutic Indications

Ahmed M Kabel1, 2,

1Department of Clinical Pharmacy, College of Pharmacy, Taif University, Taif, Saudi Arabia

2Department of Pharmacology, Faculty of Medicine, Tanta University, Tanta, Egypt

Pub. Date: October 12, 2014

Cite this paper:
Ahmed M Kabel. Silymarin: Insights into Properties and Therapeutic Indications. World Journal of Nutrition and Health. 2014; 2(3):33-34. doi: 10.12691/jnh-2-3-1

Abstract

Silymarin is the active ingredient of milk thistle. Several studies proved that silymarin has antioxidant, anti-inflammatory and anti-cancer properties. Silymarin is widely used for treatment of hepatic and biliary disorders, renal toxicity and is recently used as adjuvant agent for treatment of cancer.

Keywords:
silymarin properties indications

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  Nancy Vargas-Mendoza, Eduardo Madrigal-Santillán, Ángel Morales-González, Jaime Esquivel-Soto, Cesar Esquivel-Chirino, Manuel García-Luna y González-Rubio, Juan A Gayosso-de-Lucio, José A Morales-González (2014). Hepatoprotective effect of silymarin. World J Hepatol; 6 (3): 144-149.
 
[2]  Karimi G, Vahabzadeh M, Lari P, Rashedinia M, Moshiri M (2011). “Silymarin”, a promising pharmacological agent for treatment of diseases. Iran J Basic Med Sci; 14: 308-317.
 
[3]  Cacciapuoti F, Scognamiglio A, Palumbo R, Forte R, Cacciapuoti F (2013). Silymarin in non alcoholic fatty liver disease. World J Hepatol; 5: 109-113.
 
[4]  Morazzoni P, Montalbetti A, Malandrino S (1993). Comparative pharmacokinetics of silipide and silymarin in rats. Eur J Drug Metab Pharmacokinet; 18: 289-297.
 
[5]  Turgut F, Bayrak O, Catal F, Bayrak R, Atmaca AF et al. (2008). Antioxidant and protective effects of silymarin on ischemia and reperfusion injury in the kidney tissues of rats. Int Urol Nephrol J; 40 (2): 453-460.
 
[6]  Fraschini F, Demartini G, Esposti D (2002). Pharmacology of silymarin.Clin Drug Invest; 22 (1): 51-65.
 
[7]  Kwon do Y, Jung YS, Kim SJ, Kim YS, Choi DW, Kim YC (2013). Alterations in sulfur amino acid metabolism in mice treated with silymarin: a novel mechanism of its action involved in enhancement of the antioxidant defense in liver. Planta Med; 79: 997-1002.
 
[8]  Toklu HZ, Tunali-Akbay T,Erkanli G, Yuksel M, Ercan F, Sener G (2007). Silymarin,the antioxidant component of Silybum marianum,protects against burn induced oxidative skin injury. Burns; 33:908-916.
 
[9]  Soto C, Recoba R, Barron H, Alvarez C, Favari L (2003). Silymarin increases antioxidant enzymes in alloxan-induced diabetes in rat pancreas. Comp Biochem Physiol C Toxicol Pharmacol; 136: 205-212.
 
[10]  Karimi G, Ramezani M, Tahoonian Z (2005). Cisplatin nephrotoxicity and protection by milk thistle extract in Rats. Evid Based Complement Alternat Med; 2 (3):383-6.
 
[11]  Fraschini F, Demartini G, Esposti D (2002). Pharmacology of silymarin.Clin Drug Invest; 22 (1):51-65.
 
[12]  Polyak SJ, Morishima C, Shuhart MC, Wang CC, Liu Y, Lee DY (2007). Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin. Gastroenterology; 132: 1925-1936.
 
[13]  Wilasrusmee C, Kittur S, Shah G, Siddiqui J, Bruch D et al. (2002). Immunostimulatory effect of Silybum marianum (milk thistle) extract. Med Sci Monit; 8: 439- 43.
 
[14]  Su CH, Chen LJ, Liao JF, Cheng JT (2013). Dual effects of silymarin on nasopharyngeal carcinoma cells (NPC-TW01). Forsch Komplementmed; 20: 261-266.
 
[15]  Lee MH, Huang Z, Kim DJ, Kim SH, Kim MO, Lee SY, Xie H, Park SJ, Kim JY, Kundu JK, Bode AM, Surh YJ, Dong Z (2013). Direct targeting of MEK1/2 and RSK2 by silybin induces cell-cycle arrest and inhibits melanoma cell growth. Cancer Prev Res (Phila); 6: 455-465
 
[16]  Loguercio C, Festi D (2011). Silybin and the liver: from basic research to clinical practice. World J Gastroenterol; 17: 2288-2301.
 
[17]  Polyak SJ, Morishima C, Lohmann V, Pal S, Lee DY, Liu Y, Graf TN, Oberlies NH (2010). Identification of hepatoprotective flavonolignans from silymarin. Proc Natl Acad Sci USA; 107: 5995-5999.
 
[18]  Kabel AM, Mahmoud HA, El Kholy SS (2013). Ameliorative potential of gemfibrozil and silymarin on experimentally induced nephrotoxicity in rats. Afr J Urol; 19 (4): 171-178.
 
[19]  Abou Zid S (2012). Silymarin, Natural Flavonolignans from Milk Thistle. In: Venketeshwer R. Phytochemicals-A Global Perspective of Their Role in Nutrition and Health. Rijeka: Croatia InTech, 2012: 255-272.